A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs).

A randomized phase 2 trial is being conducted to compare the effectiveness of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine, which work to produce normal blood cells and kill abnormal cells in the bone marrow. Iadademstat may stop tumor cell growth by blocking enzymes needed for cell growth. The trial aims to assess acute leukemia response rates, event-free survival, overall survival, and other outcomes in patients with MPNs. [Extracted from the article]